Molecularly Guided Therapy in Hepatobiliary Cancers: Current Standards and Emerging Horizons.

Hepatobiliary malignancies constitute a major global oncologic burden, encompassing a heterogeneous spectrum of tumors comprised of hepatocellular carcinoma (HCC) and biliary tract cancers (BTC). While precision oncology has transformed BTC management-particularly intrahepatic cholangiocarcinoma, where molecular profiling identifies actionable alterations in FGFR2, IDH1, HER2, and other targetable pathways. The contemporary therapeutic landscape integrates targeted agents with immune checkpoint inhibitors; yet, optimal treatment sequencing and biomarker-driven patient selection require further refinement. This review synthesizes current evidence-based approaches and emerging therapeutic paradigms in hepatobiliary oncology, examining how molecular characterization can bridge the precision medicine gap between BTC and HCC to improve patient outcomes.